Patient 2 was a woman in her 60s diagnosed with stage III lCC whose tumor harbored wild-type BRAF. Pharmacologic screens in organoids from this patient (ICC-1) revealed a slight sensitivity to lenvatinib, 8 mg/d, orally. The gene discussed is BRAF; the disease is neoplasm.